Rp5063 is being approved for some kind of heart condition, not sz. For sz it hits all the familiar receptors so it will have all the side fx.
"RP5063 (also RP5000) is an atypical antipsychotic developed by Reviva Pharmaceuticals for the treatment of schizophrenia. This drug has a relatively complex mechanism of action, encompassing a variety of serotonergic and dopaminergic receptors. It functions primarily as a dopamine-serotonin system stabilizer by targeting the D2, D3, and D4 receptors and 5-HT1A and 5-HT2**A receptors as a partial agonist.**
The drug also has a high affinity for the 5-HT7 and H1 receptors. In addition, it is thought to elicit an effect on the D1, D5, 5-HT6, 5-HT3, Alpha-1B adrenergic receptor sites, and serotonin transporter (SERT). Unlike some other antipsychotics, it doesn’t significantly affect neurotransmission at the 5-HT1B, 5-HT2C, Alpha-2 adrenergic, and muscarinic acetylcholine receptors."